BACKGROUND: @entity5 factor alpha ( @entity1505 ) has an important role in @entity8 . @entity7428 , a type IV phosphodiesterase inhibitor, has multiple anti-inflammatory effects including inhibition of @entity1505 synthesis. METHODS: We investigated the effects of @entity7428 in prevention and delayed treatment of crescentic @entity631 in @entity35 Kyoto @entity35 . @entity631 was induced by injection of nephrotoxic serum. RESULTS: In the preventive study, @entity7428 (6.25 mg/kg i.p. twice daily) was started 2.5 h before injection of nephrotoxic serum. @entity7428 reduced the expression of @entity1505 in glomeruli and renal tubules and abrogated @entity8 on day 4 (99.7% reduction in @entity633 and 96.4% reduction in fibrin deposition). In the delayed-treatment experiment, @entity7428 was started 4 days after injection of nephrotoxic serum. @entity7428 reduced renal excretion of @entity1505 by 63% on day 7. @entity1505 was not detected in the sera of treated or control @entity35 . Delayed treatment was effective in crescentic @entity631 , as shown by reduction in @entity633 by 38.1%, fibrin deposition by 60.8%, and crescent formation by 67% on day 7. CONCLUSIONS: @entity7428 is effective both in prevention and treatment of experimental crescentic @entity631 . This was associated with a reduction of renal production of @entity1505 .

Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic XXXX .

@entity8 :: ('MESH:D007674', 'Disease') :: ['acute glomerular inflammation', 'glomerular injury'] @entity7428 :: ('MESH:D020889', 'Chemical') :: ['Rolipram', 'rolipram'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Tumour necrosis'] @entity1505 :: ('24835(Tax:10116)', 'Gene') :: ['TNF-alpha'] @entity633 :: ('MESH:D000419', 'Disease') :: ['albuminuria'] @entity35 :: ('10116', 'Species') :: ['Wistar', 'rats'] @entity631 :: ('MESH:D005921', 'Disease') :: ['glomerulonephritis', 'Glomerulonephritis']
@entity631 :: (MESH:D005921,Disease) :: ['glomerulonephritis']
